Eicosatrienoic Acid.

Gamma-linolenic acid is elongated to dihomo-gamma-linolenic acid, the 20:3 n-6 form of eicosatrienoic acid, by elongase 5. The elongation step is fast and not usually rate-limiting, which is why oral GLA raises tissue DGLA reliably. This is the single most direct route to raising this fatty acid in a person.

Evening primrose oil carries roughly 8 to 10 percent GLA, which is elongated to DGLA after absorption. It is the most common commercial way to raise this fatty acid without supplying it directly. Borage oil does the same job at a higher GLA percentage.

Delta-6 desaturase, the enzyme that converts linoleic acid to GLA and so feeds this pathway from the diet, has a documented requirement for adequate zinc status. In zinc deficiency the conversion slows and downstream 20:3 levels fall. Supplying zinc above adequacy has not been shown to push the pathway further.

Pyridoxine is described as supporting delta-6 desaturase activity in the conversion of linoleic acid onward. The evidence sits mostly in older animal and enzyme work rather than in human intervention data. Correcting a shortfall is the defensible framing.

Magnesium is required by the enzyme systems that desaturate and elongate dietary fatty acids toward the 20-carbon products. As with zinc, this is a story about adequacy rather than about loading. It matters most where intake is genuinely low.

Any 20-carbon fatty acid with three double bonds is vulnerable to peroxidation both in the bottle and in the membrane. Tocopherol is the standard co-formulated antioxidant for polyunsaturated oils, and higher PUFA intake raises the tocopherol requirement. This is oxidative protection, not a functional partnership.

EPA competes with DGLA and arachidonic acid for the same desaturase and eicosanoid-forming enzymes, and EPA also inhibits delta-5 desaturase. The practical result is that adding EPA tends to hold DGLA at the 20:3 stage rather than letting it convert onward to arachidonic acid. Formulators use that competition deliberately, which is why GLA and fish oil are so often combined.

Combining a GLA source with fish oil is standard practice because the omega-3s restrain delta-5 desaturase and slow the conversion of DGLA to arachidonic acid. The pairing shapes where the pathway stalls. The reasoning is mechanistic, and the clinical size of the difference is not settled.

Dietary linoleic acid is the origin of the n-6 series and is desaturated to GLA before elongation to DGLA. The delta-6 desaturase step is slow and easily rate-limiting, which is why supplying linoleic acid is a far less efficient route to 20:3 n-6 than supplying GLA directly.

Astaxanthin sits across the membrane bilayer and quenches lipid radicals in the same phase where polyunsaturated fatty acids oxidise. It is used alongside PUFA oils on those grounds. The protection is chemically sound. A downstream benefit in a person has not been demonstrated for this specific pairing.

Phospholipid emulsifiers disperse long-chain fatty acid oils into finer droplets, which increases the surface available to pancreatic lipase. Fatty acid absorption is already efficient, so the gain here is mostly about formulation stability and tolerability. It is a delivery aid.

When this fatty acid is supplied as a triglyceride, pancreatic lipase has to cleave it at the sn-1 and sn-3 positions before the products can be absorbed. Where lipase output is low, the released fraction is lower. Supplemental lipase addresses that specific limitation rather than improving absorption in general.